Carnegie Investment Bank

Carnegie Investment Bank is proud to have acted as financial advisor to Nordic Capital in their acquisition of a majority stake in Sensio. Sensio is a leading provider of healthcare technology, solving today's and tomorrow's care challenges for the benefit of both residents, patients, relatives, healthcare personnel and society. Sensio is headquartered in Norway and provides its solutions to several hundred care providers and operators across Norway, Sweden, Denmark, and the UK, supporting care for ca. 70 000 care recipients through its technology platform. Carnegie congratulates Nordic Capital on the successful transaction. We thank you for the vote in confidence and look forward to following the exciting growth journey.

Carnegie Investment Bank is proud to act as Joint Financial Advisor in Lifeline SPAC I ’s combination with Canatu Oy   Lifeline SPAC I Plc, listed on the SPAC segment of Nasdaq Helsinki Ltd’s regulated market, and shareholders of Canatu Oy have today concluded a share exchange agreement whereby Lifeline SPAC I acquires all shares, option rights, and other rights exchangeable to shares in Canatu by way of a directed share issue consisting of Lifeline SPAC I’s new shares to form a combined company.   Canatu is a deep technology company developing advanced carbon nanotubes (CNTs) and related products and manufacturing equipment for the semiconductor, automotive and medical diagnostics industries. These industries require extremely high-quality CNTs and offer Canatu strong growth and profitability potential.   Carnegie congratulates both parties on the transaction!

Sale of Aker BioMarine ASA’s Feed Ingredients business unit – USD 590 million   Carnegie Investment Bank acted as financial advisor to Aker BioMarine ASA in the sale of its “Feed Ingredients” business unit to American Industrial Partners and Aker Capital.     The total transaction value is USD 590 million. Following the transaction, Aker BioMarine will be a focused human health and nutrition company consisting of three business units; (1) Human Health Ingredients (2) Consumer Health Ingredients and (3) Emerging Businesses.   Carnegie once again thanks the whole Aker BioMarine team for the vote of confidence.

DOF Group has entered into an agreement to acquire Maersk Supply Service Carnegie Investment Bank is proud to act as sole financial advisor to DOF Group in the acquisition of Maersk Supply Service and joint bookrunner in the contemplated USD 100 million private placement to part-finance the acquisition. The acquisition will be paid partly in cash and partly in new shares to be issued by DOF, representing a consideration of approximately USD 1.112 billion (as of close on 28.06.2024). After issuance of the consideration shares MSSH will hold 25% of the share capital in DOF. MSS will at the time of completion of the transaction own 22 high-quality subsea and AHTS vessels, following a carve-out of certain entities, vessels, assets and liabilities. The combined company, operating under the DOF Group name and brand, will be a leading offshore service provider with comprehensive scale and a wide range of services across all continents in the offshore energy industries. DOF and MSS’ current operations are both strategically and geographically complementary, and future growth ambitions are strongly aligned. Leveraging the two global organisations' strong capabilities and competencies that will further enhance the combined company’s position as a major integrated offshore services provider. The combined company will be one of the largest oil services companies listed on the Oslo Stock Exchange. Carnegie thanks DOF Group for the vote of confidence, and we look forward to continuing our support going forward.

Penser by Carnegie acted as sole co-ordinator in the partially underwritten rights issue of approx. SEK 38 million in Lipidor AB. Lipidor is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. 

We are proud to announce that Carnegie once again has been ranked as the number one advisor for high-yield issuers in Sweden, according to the latest Kantar Sifo Prospera survey, achieving a higher overall score from clients. Thank you to our clients for your continued trust and support. #Carnegie #HighYield #FinancialAdvisory #ClientSatisfaction #MarketLeader #ESG

Summer Greetings from Carnegie

Public share offering in Faron — EUR 30.7 million Carnegie Investment Bank acted as Joint Lead Manager and Bookrunner in Faron Pharmaceuticals’ share offering of 30,709,056 newly issued treasury shares and new shares. Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system.

We are very excited to welcome our summer interns at the Oslo office, Fredrik Kjekstad Langeroed, Eirik Stray Spetalen, Torbjørn Grande, Caroline Kvamme, Olav Solheim, Erik Pettersen, and Andreas Stokke Tronsrud.    Throughout the summer, they will gain experience within either our Investment Banking or Equity Research department, working on live projects and ongoing business from day one. We are happy to have you onboard the Carnegie team!🚀

Directed new share issue in Gruvaktiebolaget Viscaria — SEK 440 million Carnegie Investment Bank acted as joint global co-ordinator and bookrunner in the directed share issue of 18,016,000 new shares at a subscription price of SEK 24.40 per share. Gruvaktiebolaget Viscaria is a company that is scaling up to become a modern and responsible producing mining company through the reopening of the Viscaria mine in Kiruna.